His primary scientific interests are in Virology, Virus, Antibody, Immunology and Viral envelope. Dani P. Bolognesi does research in Virology, focusing on Neutralizing antibody specifically. His Virus research integrates issues from Oncornavirus, Molecular biology and Molecular mass.
The concepts of his Molecular biology study are interwoven with issues in RNA and Viral protein. The Antibody study combines topics in areas such as T cell and Cytolysis. His Viral envelope research focuses on subjects like V3 loop, which are linked to Peptide and Simian immunodeficiency virus.
His main research concerns Virology, Virus, Antibody, Molecular biology and Immunology. His Virology research is mostly focused on the topic Neutralization. Dani P. Bolognesi has included themes like Cell culture, Antiserum and Cell in his Virus study.
His study in Cytolysis extends to Antibody with its themes. His work investigates the relationship between Molecular biology and topics such as Biochemistry that intersect with problems in Gp41. His Immunology study combines topics from a wide range of disciplines, such as Cytotoxic T cell and Acquired immunodeficiency syndrome.
Dani P. Bolognesi mainly focuses on Virology, Virus, Immunology, Gp41 and Peptide. His Virology study incorporates themes from Antibody, Immunogenicity and Hiv transmission. His Virus research incorporates themes from Cell culture and Immunopathology.
His Immunology study combines topics in areas such as Cytotoxic T cell and Acquired immunodeficiency syndrome. Dani P. Bolognesi combines subjects such as Heptad repeat, Lipid bilayer fusion, Transmembrane protein, Molecular biology and Transmembrane glycoprotein with his study of Gp41. As a member of one scientific family, Dani P. Bolognesi mostly works in the field of Peptide, focusing on Coiled coil and, on occasion, Leucine zipper.
Dani P. Bolognesi spends much of his time researching Virology, Virus, Immunology, Antibody and Neutralizing antibody. A large part of his Virology studies is devoted to Neutralization. His research integrates issues of Peptide analog and HIV Protease Inhibitor in his study of Virus.
His studies in Immunology integrate themes in fields like Acquired immunodeficiency syndrome and Disease. His work on Titer as part of general Antibody study is frequently linked to CXCR4, therefore connecting diverse disciplines of science. His Neutralizing antibody research is multidisciplinary, incorporating elements of Vaccinia and Immunogenicity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
H Mitsuya;K J Weinhold;P A Furman;M H St Clair.
Proceedings of the National Academy of Sciences of the United States of America (1985)
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
P A Furman;J A Fyfe;M H St Clair;K Weinhold.
Proceedings of the National Academy of Sciences of the United States of America (1986)
POTENT SUPPRESSION OF HIV-1 REPLICATION IN HUMANS BY T-20, A PEPTIDE INHIBITOR OF GP41-MEDIATED VIRUS ENTRY
J M Kilby;S Hopkins;T M Venetta;B DiMassimo.
Nature Medicine (1998)
ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
Robert Yarchoan;Kent J. Weinhold;H. Kim Lyerly;Edward Gelmann.
The Lancet (1986)
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
K Javaherian;A J Langlois;C McDanal;K L Ross.
Proceedings of the National Academy of Sciences of the United States of America (1989)
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Carl Wild;Terrence Oas;Charlene McDanal;Dani Bolognesi.
Proceedings of the National Academy of Sciences of the United States of America (1992)
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides
Thomas J. Palker;Michael E. Clark;Alphonse J. Langlois;Thomas J. Matthews.
Proceedings of the National Academy of Sciences of the United States of America (1988)
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Tom Matthews;Miklos Salgo;Michael Greenberg;Jain Chung.
Nature Reviews Drug Discovery (2004)
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1
Kashi Javaherian;Alphonse J. Langlois;Greg J. Larosa;Albert T. Profy.
Recurrent glioblastoma treated with recombinant poliovirus
Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier.
The New England Journal of Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: